Drug-related cardiotoxicity, an important issue affecting the medication safety of the public, refers to the pharmacodynamic effect of low-dose drugs that affect cardiac physiological function or cause myocardial damage in a short time. Up to now, there are dozens of drugs reported to induce cardiotoxicity in clinical use, including anti-cancer drugs, antibacterial drugs, antiallergic drugs and anesthesia drugs. Besides, concomitant drugs increase the risk of drug-induced cardiotoxicity, which could be explained by two mechanisms. On one hand, the interaction between concomitant drugs increase plasma concentration by effecting drug metabolism. On the other hand, each of the concomitant drugs alone tends to induce cardiotoxicity itself. In clinical settings, drug use should be safe, standardized and rationalized. Certain strategies, guidelines and procedures should be implemented when using cardiotoxic drugs on patients with risk factors, such as assessing cardiac function, using protective agents against cardiac toxicity, and drug interaction. And as of today, there is no effective methods for treatment of cardiotoxicity.
In this Research Topic, we would like to shed lights on the effective ways for early identification of cardiotoxicity of drugs, screening of risk factors in patients, as well as assessing strategies and preventive guidelines for cardiotoxicity drugs.
We welcome Original Article, Review and Mini Review in the subtopics of interest, which include, but not limited to the subtopics below:
1) Risk factors for drug-related cardiotoxicity.
2) Surveillance (monitoring) and cardiac imaging.
3) Assessment of drug-induced cardiotoxicity by anti-cancer drugs, antibacterial drugs, antiallergic drugs, anaesthetic drugs,
4) Drug-induced cardiotoxicity in special groups (children, pregnant women, etc).
5) Genetic mechanism of drug-related cardiotoxicity.
6) Prevention and biomarkers.
7) Cardiac function assessment prior to treatment.
8) Monitoring potential cardiotoxicity during the therapy.
9) Establishing predicting model for long-term risk evaluation.
10) Evaluation of heart-protecting drugs for future clinical recommendation usage.
Drug-related cardiotoxicity, an important issue affecting the medication safety of the public, refers to the pharmacodynamic effect of low-dose drugs that affect cardiac physiological function or cause myocardial damage in a short time. Up to now, there are dozens of drugs reported to induce cardiotoxicity in clinical use, including anti-cancer drugs, antibacterial drugs, antiallergic drugs and anesthesia drugs. Besides, concomitant drugs increase the risk of drug-induced cardiotoxicity, which could be explained by two mechanisms. On one hand, the interaction between concomitant drugs increase plasma concentration by effecting drug metabolism. On the other hand, each of the concomitant drugs alone tends to induce cardiotoxicity itself. In clinical settings, drug use should be safe, standardized and rationalized. Certain strategies, guidelines and procedures should be implemented when using cardiotoxic drugs on patients with risk factors, such as assessing cardiac function, using protective agents against cardiac toxicity, and drug interaction. And as of today, there is no effective methods for treatment of cardiotoxicity.
In this Research Topic, we would like to shed lights on the effective ways for early identification of cardiotoxicity of drugs, screening of risk factors in patients, as well as assessing strategies and preventive guidelines for cardiotoxicity drugs.
We welcome Original Article, Review and Mini Review in the subtopics of interest, which include, but not limited to the subtopics below:
1) Risk factors for drug-related cardiotoxicity.
2) Surveillance (monitoring) and cardiac imaging.
3) Assessment of drug-induced cardiotoxicity by anti-cancer drugs, antibacterial drugs, antiallergic drugs, anaesthetic drugs,
4) Drug-induced cardiotoxicity in special groups (children, pregnant women, etc).
5) Genetic mechanism of drug-related cardiotoxicity.
6) Prevention and biomarkers.
7) Cardiac function assessment prior to treatment.
8) Monitoring potential cardiotoxicity during the therapy.
9) Establishing predicting model for long-term risk evaluation.
10) Evaluation of heart-protecting drugs for future clinical recommendation usage.
